Literature DB >> 22055653

Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid.

Panagiotis Alexopoulos1, Amalia Tsolakidou, Francesco Roselli, Anila Arnold, Timo Grimmer, Christine Westerteicher, Maria Rosaria Leante, Hans Förstl, Paolo Livrea, Alexander Kurz, Robert Perneczky.   

Abstract

BACKGROUND: According to a widely accepted hypothesis, the amyloid precursor protein (APP) is processed by two competing pathways: the amyloidogenic β-secretase-mediated pathway or the nonamyloidogenic α-secretase-mediated pathway. APP is cleaved preferentially through the nonamyloidogenic pathway in normal brain, whereas the balance shifts to the amyloidogenic pathway in Alzheimer's disease (AD). The levels of the α-secretase-cleaved soluble APP (sAPPα) and β-secretase-cleaved soluble APP (sAPPβ) in cerebrospinal fluid (CSF) are likely to reflect these competing mechanisms.
METHODS: We investigated the levels and the relationship between sAPPα and sAPPβ in the CSF of 64 patients with mild AD, 76 patients with mild cognitive impairment, and 12 cognitively healthy control subjects, as well as the effect of apolipoprotein E genotype and sex on soluble APP levels.
RESULTS: There was a significant positive correlation between sAPPα and sAPPβ levels in all three groups. sAPPα and sAPPβ concentrations were higher in patients with mild cognitive impairment compared with patients with AD. In the AD group, females exhibited higher sAPPα and sAPPβ levels than males. No influence of the apolipoprotein E genotype on soluble APP concentrations was detected. DISCUSSION: The positive correlation between sAPPα and sAPPβ challenges the hypothesis that AD is caused by an imbalance of the α- and β-secretase APP proteolysis through competing mechanisms. Moreover, the differences in CSF levels of sAPPα and sAPPβ between male and female patients with AD may reflect a "sexual dimorphism" in the activity of the two APP processing pathways in AD.
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22055653     DOI: 10.1016/j.jalz.2011.04.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  13 in total

1.  CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Authors:  Justyna A Dobrowolska; Maria S Michener; Guoxin Wu; Bruce W Patterson; Robert Chott; Vitaliy Ovod; Yuriy Pyatkivskyy; Kristin R Wildsmith; Tom Kasten; Parker Mathers; Mandy Dancho; Christina Lennox; Brad E Smith; David Gilberto; Debra McLoughlin; Daniel J Holder; Andrew W Stamford; Kevin E Yarasheski; Matthew E Kennedy; Mary J Savage; Randall J Bateman
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

2.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

3.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

4.  Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Jennifer Roesler; Nathalie Thierjung; Lukas Werle; Dorothea Buck; Igor Yakushev; Lena Gleixner; Simone Kagerbauer; Marion Ortner; Timo Grimmer; Hubert Kübler; Jan Martin; Nikolaos Laskaris; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-08       Impact factor: 5.270

5.  Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment.

Authors:  Wataru Araki; Kazutomi Kanemaru; Kotaro Hattori; Tadashi Tsukamoto; Yuko Saito; Sumiko Yoshida; Harumasa Takano; Masuhiro Sakata; Yuma Yokoi; Yoshie Omachi; Utako Nagaoka; Masahiro Nagao; Takashi Komori; Hisateru Tachimori; Shigeo Murayama; Hidehiro Mizusawa
Journal:  Aging Clin Exp Res       Date:  2021-07-20       Impact factor: 3.636

Review 6.  Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease.

Authors:  Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Aitana Sogorb-Esteve; María-Salud García-Ayllón; Javier Sáez-Valero
Journal:  Front Neurol       Date:  2015-06-02       Impact factor: 4.003

7.  Heteromers of amyloid precursor protein in cerebrospinal fluid.

Authors:  Inmaculada Cuchillo-Ibañez; Inmaculada Lopez-Font; Alba Boix-Amorós; Gunnar Brinkmalm; Kaj Blennow; Jose-Luis Molinuevo; Javier Sáez-Valero
Journal:  Mol Neurodegener       Date:  2015-01-08       Impact factor: 14.195

8.  No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.

Authors:  Claudia Cicognola; Davide Chiasserini; Paolo Eusebi; Ulf Andreasson; Hugo Vanderstichele; Henrik Zetterberg; Lucilla Parnetti; Kaj Blennow
Journal:  Mol Neurodegener       Date:  2016-09-07       Impact factor: 14.195

9.  Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.

Authors:  Maria L Maccecchini; Mee Young Chang; Catherine Pan; Varghese John; Henrik Zetterberg; Nigel H Greig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-11       Impact factor: 10.154

10.  Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.

Authors:  Justyna A Dobrowolska; Tom Kasten; Yafei Huang; Tammie L S Benzinger; Wendy Sigurdson; Vitaliy Ovod; John C Morris; Randall J Bateman
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.